biostudies-literatureUnknown5(3)Schonfeld SJ<h4>Importance</h4>Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.<h4>Objective</h4>To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.<h4>Design, setting, and participants</h4>A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked datJAMA network opene223461https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941351biostudies-literatureImmune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.PMC8941351Sampson JNDores GMChanock SJMorton LMShiels MSSchonfeld SJEngels EATucker MAfalseImmune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.<h4>Importance</h4>Immune checkpoint inhibitors (ICIs) have improved survival in patients with advanced melanoma but can be associated with a spectrum of immune-related adverse events (AEs), including both autoimmune-related AEs and other immune-related inflammatory AEs. These associations have primarily been evaluated in clinical trials that include highly selected patients, with older adults often underrepresented.<h4>Objective</h4>To evaluate the association between use of ICIs and immune-related AEs (autoimmune and other immune related) among older patients with cutaneous melanoma.<h4>Design, setting, and participants</h4>A population-based cohort study was conducted from January 1, 2011, to December 31, 2015. Data were analyzed from January 31 to May 31, 2021. With use of a linked dat2022-01-01T00:00:00Z2022 Mar2025-04-04T22:17:21.375Z2025-04-04T22:17:21.375ZS-EPMC89413513531591610.1001/jamanetworkopen.2022.3461